Cargando…

Inhibition of the miR-192/215–Rab11-FIP2 axis suppresses human gastric cancer progression

Less than a century ago, gastric cancer (GC) was the most common cancer throughout the world. Despite advances in surgical, chemotherapeutic, and radiotherapeutic treatment, GC remains the number 3 cancer killer worldwide. This fact highlights the need for better diagnostic biomarkers and more effec...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Xiaojing, Peng, Yin, Huang, Yong, Deng, Shiqi, Feng, Xianling, Hou, Gangqiang, Lin, Huijuan, Wang, Jian, Yan, Ruibin, Zhao, Yanqiu, Fan, Xinmin, Meltzer, Stephen J., Li, Song, Jin, Zhe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6045576/
https://www.ncbi.nlm.nih.gov/pubmed/30006518
http://dx.doi.org/10.1038/s41419-018-0785-5
Descripción
Sumario:Less than a century ago, gastric cancer (GC) was the most common cancer throughout the world. Despite advances in surgical, chemotherapeutic, and radiotherapeutic treatment, GC remains the number 3 cancer killer worldwide. This fact highlights the need for better diagnostic biomarkers and more effective therapeutic targets. RAB11-FIP2, a member of the Rab11 family of interacting proteins, exhibits potential tumor suppressor function. However, involvement of RAB11-FIP2 in gastric carcinogenesis is yet to be elucidated. In this study, we demonstrated that RAB11-FIP2 was downregulated in GC tissues and constituted a target of the known onco-miRs, miR-192/215. We also showed that functionally, Rab11-FIP2 regulation by miR-192/215 is involved in GC-related biological activities. Finally, RAB11-FIP2 inhibition by miR-192/215 affected the establishment of cell polarity and tight junction formation in GC cells. In summary, this miR-192/215–Rab11-FIP2 axis appears to represent a new molecular mechanism underlying GC progression, while supplying a promising avenue of further research into diagnosis and therapy of GC.